impact factor
logo
 

A. Clinical considerations

 

Treat-to-target: measures


 

CER5986
2012 Vol.30, N°4 ,Suppl.73
PI 0007, PF 0009
A. Clinical considerations

Free to view
(click on article PDF icon to read the article)

PMID: 23073309 [PubMed]

Received: 14/09/2012
Accepted : 19/09/2012
In Press: 18/10/2012
Published: 19/11/2012

Abstract

Current approach to rheumatoid arthritis (RA) treatment combines early and aggressive therapy, with methotrexate as the anchor medication and monitoring disease activity to achieve the best possible outcome for patients. To recognise which patients are responding treatment and reaching low disease activity levels or remission, an objective outcome measure needs to be utilised in routine clinical care. DAS28, SDAI, CDAI and RAPID3 are all validated and similarly functioning measures that can be of use in everyday care, allowing rheumatologists to treat-to-target. The main challenge remains getting all rheumatologists to start using one of these measures as part of the care they provide.

Rheumatology Article